Biotech News

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Biodesix (BDSX)Biodesix2026-10-13 10:00 ESTCompany update

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

Related news

BDSXBiodesix2026-05-11 13:17 EST

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

BDSXBiodesix2026-03-20 12:06 EST

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

BIAFbioAffinity Technologies, Inc.2026-10-15 12:00 EST

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

BIAFbioAffinity Technologies, Inc.2026-10-13 12:00 EST

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

INBSIntelligent Bio Solutions2026-07-21 12:30 EST

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

INBSIntelligent Bio Solutions2026-06-16 12:30 EST

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

DGXQuest Diagnostics2026-09-16 12:03 EST

Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

RHHBYRoche Holdings AG2026-10-19 05:00 EST

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

View all latest news

Biodesix

Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations. Diagnostic Testing The company provides blood-based and...

Recent company news

BDSXBiodesix2026-10-22 10:00 EST

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

BDSXBiodesix2026-10-19 20:01 EST

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

BDSXBiodesix2026-10-19 10:00 EST

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

BDSXBiodesix2026-10-13 10:00 EST

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

BDSXBiodesix2026-09-24 10:00 EST

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Stock data

Close: 23.94 USD
Market cap: 159.89M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States